Amgen (AMGN) Competitors $295.27 -5.10 (-1.70%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$295.25 -0.02 (-0.01%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMGN vs. GILD, MRNA, VRTX, ABBV, BMY, JNJ, LLY, MRK, PFE, and REGNShould you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "medical" sector. Amgen vs. Its Competitors Gilead Sciences Moderna Vertex Pharmaceuticals AbbVie Bristol Myers Squibb Johnson & Johnson Eli Lilly and Company Merck & Co., Inc. Pfizer Regeneron Pharmaceuticals Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk. Is GILD or AMGN more profitable? Gilead Sciences has a net margin of 20.76% compared to Amgen's net margin of 17.39%. Amgen's return on equity of 176.11% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences20.76% 51.93% 17.40% Amgen 17.39%176.11%12.39% Do insiders and institutionals have more ownership in GILD or AMGN? 83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is GILD or AMGN a better dividend stock? Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.9%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has increased its dividend for 10 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Which has more volatility and risk, GILD or AMGN? Gilead Sciences has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Does the media refer more to GILD or AMGN? In the previous week, Amgen had 2 more articles in the media than Gilead Sciences. MarketBeat recorded 51 mentions for Amgen and 49 mentions for Gilead Sciences. Amgen's average media sentiment score of 1.55 beat Gilead Sciences' score of 1.22 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 32 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 46 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable valuation and earnings, GILD or AMGN? Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$28.75B4.74$480M$4.7523.08Amgen$33.42B4.75$4.09B$10.9626.94 Do analysts prefer GILD or AMGN? Gilead Sciences presently has a consensus target price of $111.38, indicating a potential upside of 1.59%. Amgen has a consensus target price of $307.82, indicating a potential upside of 4.25%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 9 Hold rating(s) 14 Buy rating(s) 3 Strong Buy rating(s) 2.77Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35 SummaryAmgen beats Gilead Sciences on 13 of the 20 factors compared between the two stocks. Get Amgen News Delivered to You Automatically Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMGN vs. The Competition Export to ExcelMetricAmgenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.51B$2.99B$5.60B$9.11BDividend Yield3.17%2.39%5.24%4.02%P/E Ratio26.9420.5827.9620.25Price / Sales4.75291.28430.5799.61Price / Cash9.8942.8637.4658.16Price / Book27.017.638.045.49Net Income$4.09B-$55.05M$3.18B$250.27M7 Day Performance-1.00%8.39%3.63%4.75%1 Month Performance-0.68%5.35%4.04%7.64%1 Year Performance-10.75%1.95%29.56%16.34% Amgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMGNAmgen4.4352 of 5 stars$295.27-1.7%$307.82+4.2%-9.2%$161.51B$33.42B26.9428,000Positive NewsAnalyst RevisionGILDGilead Sciences4.9356 of 5 stars$111.18-0.5%$110.55-0.6%+56.7%$138.28B$28.75B23.4017,600Positive NewsAnalyst RevisionMRNAModerna4.3068 of 5 stars$30.09-1.3%$46.61+54.9%-72.6%$11.64B$3.24B-3.455,800Trending NewsVRTXVertex Pharmaceuticals4.3267 of 5 stars$459.20-0.1%$511.62+11.4%-4.7%$117.92B$11.10B-117.146,100Positive NewsAnalyst RevisionABBVAbbVie4.4966 of 5 stars$187.56-0.9%$211.29+12.6%+13.2%$331.88B$56.33B79.9555,000Trending NewsAnalyst RevisionBMYBristol Myers Squibb4.8973 of 5 stars$46.58-0.7%$58.00+24.5%+15.1%$94.85B$48.30B17.4634,100Trending NewsAnalyst ForecastAnalyst RevisionJNJJohnson & Johnson4.7706 of 5 stars$155.19-0.5%$170.88+10.1%+4.8%$373.87B$88.82B17.28138,100Trending NewsUpcoming EarningsAnalyst ForecastLLYEli Lilly and Company4.982 of 5 stars$770.04-1.4%$1,011.61+31.4%-15.1%$731.18B$45.04B62.7747,000Trending NewsAnalyst ForecastAnalyst RevisionMRKMerck & Co., Inc.4.994 of 5 stars$81.12+0.2%$109.19+34.6%-35.3%$203.94B$64.17B11.8275,000Trending NewsAnalyst ForecastAnalyst RevisionPFEPfizer4.9693 of 5 stars$25.27-0.5%$28.55+13.0%-10.5%$143.87B$63.63B18.3481,000Trending NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.8344 of 5 stars$537.13-1.9%$813.57+51.5%-47.4%$58.04B$14.20B13.6915,106Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies GILD Competitors MRNA Competitors VRTX Competitors ABBV Competitors BMY Competitors JNJ Competitors LLY Competitors MRK Competitors PFE Competitors REGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMGN) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
